

Nanoligent raised €2.8 M and completed Seed round financing with support of i&i Biotech Fund I

The final closing of the Seed round consists of € 1 M investment by i&i Bio. i&i Bio joined previous investors, Italian Angels for Growth and AVANTECA Partners.

PRAGUE, CZECH REPUBLIC, September 27, 2022 /EINPresswire.com/ --

[Nanoligent](#) SL, a Spanish biotech company specialized in the development of cancer treatments based on unique protein conjugates, today announces the completion of a Seed financing round of total € 2.8 M. The final closing of the Seed round consists of € 1 M investment by [i&i Biotech Fund I](#) (i&i Bio), an early-stage Life Science fund with teams in Luxemburg and Prague which is backed by the European Investment Fund. i&i Bio joined previous Nanoligent investors, Italian Angels for Growth, the largest network of business angels in Italy, and AVANTECA Partners, a Swiss privately held asset management firm.




From left: M. Rodríguez Mariscal (Nanoligent), J. Zahrádka and B. Sumova (i&i Bio), M. Milos (Avanteca), M. Cano (Nanoligent), M. Marzola (IAG), R. Mangues (IIB S. Pau), P. Álamo (Nanoligent), A. Villaverde (IBB-UAB), I. Casanovas, L. Alba, U. Unzueta (all IIB S. Pau).

Jaromir Zahrádka, Managing partner of i&i Bio, said: "Nanoligent is the fifth investment of our fund and it belongs to a group of targeted oncology therapies in our portfolio. We are excited by deep scientific background and uniqueness of the technology. The platform is developed by highly motivated, experienced, and fully engaged team of scientists and managers. Based on obtained scientific data, the project has a great potential to become an effective treatment for multiple metastatic-cancer types."

Nanoligent is focused on the development of new drugs for the treatment of more than 20

different metastatic cancer types. The lead molecule is based on the targeted elimination of cancer cells overexpressing the CXCR4 receptor, a recognized biomarker for poor prognosis and therapy resistance. Nanoligent is developing a new proprietary nano-technological platform, with the potential to overcome current limitations of Antibody-Drug-Conjugates.

“Less than a third of newly diagnosed metastatic patients respond to current therapies, making metastasis one of the most pressing unsolved challenges in cancer. With the support of i&i Bio together with our existing investors, we secure our current milestone to provide the first drug candidate of our portfolio of metastasis-targeted therapies” said Montserrat Cano, CEO of Nanoligent. The seed round financing will allow Nanoligent to foster the development of multiple drug candidates and advance the pre-clinical development of its lead candidate in a variety of tumor types.



From left to right: E. Vázquez (IBB UAB), N. Serna (Research Scientist Nanoligent), B. Sumova (i&i Bio), A. Livieri (Research Scientist Nanoligent), M. Cano (CEO Nanoligent), E. Parladé (IBB UAB), M. Rodríguez Mariscal (Chairman of Nanoligent), J. Zahradka (i&i Bio).

“

Based on obtained scientific data, the project has a great potential to become an effective treatment for multiple metastatic-cancer types.”

Jaromir Zahradka, Managing partner of i&i Biotech Fund

“We are happy to welcome the i&i Biotech Fund I in Nanoligent. As in previous cases, we have been impressed by the depth of their scientific due diligence and the professionalism of their management. They are going to be an important partner for Nanoligent and we are delighted to continue to co-invest with i&i Bio,” said Michele Marzola who, together with Alessandro Toniolo, are co-champions from IAG in this investment.

Two of the investors already joined the Nanoligent’s Board which includes: Michele Marzola (IAG), Michael Milos

(Avanteca Partners), Manuel Rodríguez (Chairman) and Montserrat Cano (CEO).

“The i&i Biotech Fund I is the right partner for the further development of Nanoligent. They have shown in depth scientific knowledge as well as being well connected within the pharmaceutical network. We all together are looking forward to bringing Nanoligent’s development plan

effectively to the next stages,” said Michael Milos from AVANTECA Partners.

Contact:

Martin Kovalčík, + 420 777 472 863, <mailto:kovalcik@inibio.eu> (for i&i Biotech Fund)

Montserrat Cano, + 34 617 140 405, mcano@nanoligent.com (for Nanoligent)

Martin Kovalčík

i&i Biotech Fund I SCSp

+420 777 472 863

[email us here](#)

Visit us on social media:

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/593014556>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.